|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
133 (66.5%) ESFT displayed one of the above EWSR1-ETS translocations.
|
27180056 |
2016 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ewing sarcoma family of tumors share recurrent translocations that fuse EWS from 22q12 to five different members of transcription factors namely FLI-1, ERG, ETV1, E1AF and FEV.
|
10949935 |
2000 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ewing sarcoma family of tumors research has benefited from new target discovery and enhanced biologic understanding of the EWS-FLI1 fusion protein.
|
15659957 |
2005 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tumors of the Ewing family are characterized by chromosomal translocations that yield chimeric transcription factors, such as EWS/FLI1, which regulate the expression of specific genes that contribute to the malignant phenotype.
|
17438102 |
2007 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ewing sarcoma family of tumors (ESFTs) are characterized by the t(11;22)(q24;q12) translocation that generates the Ewing sarcoma breakpoint region 1 and Friend leukemia virus integration 1 (EWS-FLI1) fusion transcription factor responsible for the highly malignant phenotype of this tumor.
|
21653923 |
2011 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ewing's sarcoma family of tumors (EFT) is characterized by the presence of chromosomal translocations leading to the expression of oncogenic transcription factors such as, in the majority of cases, EWS/FLI1.
|
22323082 |
2012 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ewing sarcoma/peripheral primitive neuroectodermal tumor (EWS/pPNET) and other tumors with EWS gene rearrangements encompass a malignant and intermediate neoplasm with a broad anatomic distribution and a wide age range but a predilection for soft tissue in children, adolescents, and young adults.
|
22420726 |
2012 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ewing's sarcoma family of tumors (EFT) contain reciprocal translocations, of which approximately 90% occur between the long arm of chromosomes 11 and 22,t(11;22)(q24;q12) resulting in the formation of chimeric proteins generated by a fusion of the EWS and FLI-1 genes.
|
9049825 |
1997 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
EWS gene rearrangements, present in essentially 100% of Ewing's Sarcoma/peripheral primitive neuroectodermal tumor, were evaluated by FISH on frozen sections (FS) of tumor biopsies from 10 patients, plus a negative control, and in seven other malignant neoplasms of childhood.
|
10078922 |
1999 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors.
|
15930281 |
2005 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
EWS/FLI1 inhibition results in a novel adaptive response and suggests that targeting the IL6/STAT3 signaling pathway may increase the efficacy of ESFT therapies.
|
25092916 |
2014 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
EWS-erg and EWS-Fli-1, which are involved in greater than 95% of Ewing family of tumors, were shown to function as transcriptional activators.
|
9178886 |
1997 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
All cases of ESFT were confirmed to have a rearranged EWS gene.
|
16721801 |
2006 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
An origin in the head and neck and the presence of the typical EWS/FLI1, in conjunction with an opportunity for immediate treatment, may predict a relatively better prognosis for EFT in our case.
|
25755803 |
2015 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As a result of the t(11;22)(q24;q12) chromosomal translocation characterizing the Ewing family of tumors (ET), the amino terminal portion of EWS, an RNA binding protein of unknown function, is fused to the DNA-binding domain of the ets transcription factor Fli1.
|
9704926 |
1998 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, it was not until the discovery that these tumors share a common underlying molecular pathogenesis (chromosomal translocations involving the EWS gene and one of several members of the ETS family of transcription factors) that significant advances in the diagnosis and therapy of ESFT became possible.
|
18088234 |
2008 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chromosomal translocation t(11;22)(q24:q12) results in the formation of EWS/FLI1 gene fusion, which is detected in approximately 90% of tumors of the Ewing family.
|
29581854 |
2018 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytopathological findings of primary pulmonary Ewing family of tumors with EWSR1 translocation: A case report.
|
27766786 |
2016 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of EWS-FLI-1 fusion in Ewing's sarcoma/peripheral primitive neuroectodermal tumor by fluorescence in situ hybridization using formalin-fixed paraffin-embedded tissue.
|
10088552 |
1999 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection of EWSR1 translocations - particularly t(11;22)(q24;q12) - is of great value in the differential diagnosis of the Ewing family of tumors.
|
20513536 |
2010 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endogenous RHA was identified in a protein complex with EWS-FLI1 in ESFT cell lines.
|
16740692 |
2006 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ewing's Sarcoma Oncogene (ews) on chromosome 22q12 is encoding a ubiquitously expressed RNA-binding protein (EWS) with unknown function that is target of tumor-specific chromosomal translocations in Ewing's sarcoma family of tumors.
|
25688366 |
2015 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
Experiments using ESFT cell lines or animal xenograft models have proven that EWS-FLI1 is required for tumor survival.
|
16556028 |
2005 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
First, we analyzed the expression of CAV1 by immunostaining a tissue microarray containing 43 paraffin-embedded ESFT tumors with known EWS translocations.
|
21106507 |
2010 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fluorescence in situ hybridization (FISH) indicated a rearrangement of the EWS region on chromosome 22, which is highly specific for Ewing's sarcoma and PNET, which are referred to as the Ewing's sarcoma family of tumors (EFT).
|
17610475 |
2007 |